Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Bioretec
Tampere, Finland
- Ownership
- Private
- Development stage
- Other
01
Overview
Bioretec's RemeOs™ absorbable magnesium alloy implants have received market authorization in the U.S. (2023) and CE mark in Europe (2025), with excellent patient results reported in initial U.S. launches. The technology enables fracture healing without the need for implant removal surgeries, improving recovery and reducing healthcare costs. Activa™ self-reinforced PLGA polymer products are also fully commercialized.[1][2][3][4]
- Therapeutic areas
- NeurologyRheumatologyOther
- Modalities
- Device
- Industry
- Implantable Medical Devices
02
Partnerships
Tri-State Biologics (TSB)GlobalMed LogistixSpartan Medical
Beyond the preview
Go deeper on Bioretec.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bioretec.